Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.
Rani Therapeutics has raised $60.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Rani Therapeutics's investors include RA Capital Management, Novartis, AstraZeneca, Samsara BioCapital, Invus.
Rani Therapeutics is headquartered in San Jose, United States.
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.
Rani Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rani Therapeutics — Funding & Investors." VCBacked, October 17, 2025, https://www.vcbacked.co/company/rani-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Rani Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/rani-therapeutics
{{cite web |title=Rani Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rani-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated